10 Year Financial Data of Isis Pharmaceuticals (ISIS)

20.66 (1y: +120%)

Market Cap	2.09 B	P/E(ttm)
Enterprise Value	1.9 B	P/B	11.49

ISIS- NAS (USA)
Isis Pharmaceuticals

Currently 1/5

Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies

$20.66

2 Severe Warning Signs 3 Medium Warning Signs 1 Good Sign

Bookmark

Annual Rates (per share)	10 yrs*	5 yrs*	12 months*
Revenue Growth (%)	6.2	-4.4	20.8
EBITDA Growth (%)	-13.6	73.2	0
Free Cash Flow Growth (%)	0	0	0
Book Value Growth (%)	0	14.3	30.5

*12-month growth rate is calculated with the per share revenue (EBITDA, FCF, earnings) of the last 12 months over the per share revenue (EBITDA, FCF, earnings) over the previous 12 months. 5-year and 10-year growth rates are calculated with least-square regression based on the 5-year and 10-year numbers.

Trendline:

Export:

Print This Table Print

See this page for the explanation of the data and charts * All numbers are in millions except for per share data

Per Share Data	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	TTM	Mar12	Jun12	Sep12	Dec12	Mar13

Revenue per Share ($)	0.90	0.75	0.64	0.33	0.83	1.13	1.24	1.09	0.99	1.01	1.22	0.23	0.47	0.12	0.20	0.43
EBITDA per Share	-1.20	-1.87	-0.76	-0.82	-0.38	-0.07	-0.17	-0.40	-0.60	-0.58	-0.37	-0.18	0.04	-0.28	-0.15	0.02
Free Cashflow per Share	-1.86	-1.86	-0.99	-0.75	0.37	2.06	-1.27	-0.82	-1.26	-0.03	-0.08	-0.07	-0.05	-0.26	0.34	-0.11
Earnings per Share ($)	-1.73	-2.52	-1.15	-0.62	-1.63	-0.13	1.58	-0.62	-0.85	-0.65	-0.43	-0.24	-0.01	-0.37	-0.03	-0.02
Book Value per Share	1.21	-1.27	0.04	0.92	0.01	0.71	2.97	2.47	1.72	1.82	1.97	1.51	1.54	1.69	1.81	1.97
Month End Stock Price	6.50	5.90	5.24	11.12	15.75	14.18	11.11	10.12	7.21	10.44	16.94	8.77	12.00	14.07	10.44	16.94
Ratios	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

Return on Equity %	-141	--	-2,717	-67.00	-1,261	-17.80	53.20	-25.00	-49.50	-35.80	-3.20	-63.60	-3.20	-88.40	-5.60	-3.20
Return on Assets %	-28.40	-68.40	-43.50	-17.90	-4.20	-2.10	23.60	-11.10	-17.50	-12.00	-1.20	-20.40	-1.20	-30.80	-2.00	-1.20
Return on Capital - Joel Greenblatt %	-265	-681	-1,232	-2,836	--	--	--	--	-176	-97.60	16.80	-148	25.20	-175	-148	16.80
Debt to Equity	3.42	-3.43	55.44	2.05	195	2.60	0.05	0.63	1.28	0.45	1.13	1.46	1.50	1.33	0.45	1.13

Gross Margin %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
Operating Margin %	-158	-277	-143	-278	-55.90	-12.20	-22.60	-44.60	-71.80	-67.50	3.70	-79.40	7.80	-242	-131	3.70
Net Margin %	-190	-334	-180	-187	-15.80	-11.20	128	-56.50	-85.60	-64.20	-3.90	-103	-2.50	-324	-13.30	-3.90

Days Sales Outstanding	19.40	86.00	35.60	35.60	32.40	14.00	32.70	4.20	25.50	1.90	2.50	5.40	3.00	27.30	2.40	2.50

Debt to Revenue	4.60	5.80	3.68	5.72	2.44	1.63	0.13	1.42	2.21	0.81	5.24	9.48	4.88	19.52	4.17	5.24
Inventory to Revenue	0.28	0.06	0.02	0.04	0.04	0.03	0.02	0.02	0.04	0.06	0.13	0.21	0.15	0.58	0.31	0.13
Interest Exp. to Revenue %	-37.37	-53.00	-37.92	-12.51	5.56	5.33	-10.42	-9.09	-14.45	-18.92	-10.19	-19.71	-10.02	-47.66	-22.43	-10.19

Asset Turnover	0.15	0.21	0.24	0.10	0.27	0.19	0.19	0.20	0.20	0.19	0.08	0.05	0.10	0.02	0.04	0.08
Buyback Ratio	1.80	2.80	67.90	188	103	859	-8.70	7.10	4.20	14.50	--	--	--	--	2.60	--
Income Statement	Annuals (USD $) View: $ %											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	TTM	Mar12	Jun12	Sep12	Dec12	Mar13

Revenue	49.99	42.62	40.13	24.53	69.62	107	122	108	99.09	102	122	23.24	47.34	11.60	19.87	43.36
Gross Profit	49.99	42.62	40.13	24.53	69.62	107	122	108	99.09	102	122	23.24	47.34	11.60	19.87	43.36

Selling, General, &Admin. Expense	10.20	9.58	7.89	12.62	15.93	13.81	14.52	11.67	12.79	12.52	12.96	2.98	3.21	3.10	3.23	3.42
Research &Development	117	118	82.47	80.57	92.64	106	135	145	157	158	158	38.71	40.44	36.55	42.76	38.31
Earnings Before DDA	-66.73	-106	-47.49	-60.90	-32.18	-6.24	-16.21	-39.18	-59.32	-58.17	-38.09	-18.46	3.70	-28.05	-15.36	1.63

Depreciation, Depletion and Amortization	12.25	12.17	9.69	7.22	6.77	6.82	11.33	9.18	11.78	10.76	10.76	--	--	--	10.76	--

Operating Income	-78.98	-118	-57.18	-68.12	-38.95	-13.06	-27.54	-48.36	-71.10	-68.92	-48.84	-18.46	3.70	-28.05	-26.12	1.63
Interest Income/Expense	-18.68	-22.59	-15.22	-3.07	3.87	5.72	-12.67	-9.86	-14.32	-19.31	-19.15	-4.58	-4.74	-5.53	-4.46	-4.42
Net Income	-95.00	-143	-72.40	-45.90	-10.99	-11.96	155	-61.25	-84.80	-65.48	-43.16	-24.00	-1.21	-37.64	-2.64	-1.67

Preferred dividends	0.69	0.36	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Earnings per Share ($)	-1.73	-2.52	-1.15	-0.62	-1.63	-0.13	1.58	-0.62	-0.85	-0.65	-0.43	-0.24	-0.01	-0.37	-0.03	-0.02
Total Shares Outstanding	55.46	56.64	62.88	74.31	83.74	94.57	98.11	99.14	99.66	101	102	100	100	101	101	102
Balance Sheet	Annuals (USD $) View: $ %											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

Cash and cash equivalents	216	104	94.39	193	194	491	574	472	344	374	417	334	336	344	374	417
Accounts Receivable	2.66	10.05	3.92	2.40	6.18	4.12	10.90	1.24	6.92	0.52	1.17	1.38	1.56	3.48	0.52	1.17
Inventory	14.00	2.72	0.95	0.86	2.82	2.72	2.77	2.48	4.14	6.12	5.81	4.87	7.11	6.74	6.12	5.81
Other Current Assets	7.41	8.96	6.60	9.61	4.60	20.55	8.15	7.06	5.42	42.35	8.07	7.42	5.72	7.80	42.35	8.07
Total Current Assets	240	126	106	206	207	518	596	483	360	423	432	348	350	362	423	432

Property, Plant and Equipment	34.79	28.45	9.13	7.16	7.13	17.37	27.34	35.70	96.62	91.08	89.69	95.13	94.01	92.60	91.08	89.69
Intangible Assets	50.74	45.20	42.54	38.27	36.86	33.12	30.45	15.82	16.26	18.65	25.61	17.07	17.70	18.18	18.65	25.61
Other Long Term Assets	9.85	9.16	8.84	4.28	7.55	5.27	3.27	15.82	11.88	12.52	5.82	10.99	10.27	13.32	12.52	5.82
Total Assets	335	208	166	256	259	574	657	550	485	546	553	471	472	486	546	553

Accounts Payable	14.40	18.68	14.44	16.58	21.76	22.10	31.49	25.74	36.14	33.52	30.54	24.45	26.75	22.99	33.52	30.54
Current Portion of Long-Term Debt	16.48	10.55	7.84	7.51	7.24	2.07	4.27	5.65	3.39	4.88	4.51	2.94	5.31	5.18	4.88	4.51
Other Current Liabilities	14.68	14.19	1.51	1.04	33.21	101	75.68	74.50	36.58	35.93	35.24	34.32	23.00	23.43	35.93	35.24
Total Current Liabilities	45.56	43.42	23.79	25.14	62.21	125	111	106	76.11	74.32	70.30	61.71	55.06	51.60	74.32	70.30

Long-Term Debt	213	237	140	133	163	172	11.48	149	215	77.95	223	217	226	221	77.95	223
Other Long-Term Liabilities	8.81	0.53	0.00	29.38	32.92	210	243	51.28	21.90	211	58.82	40.87	37.28	42.52	211	58.82
Total Liabilities	268	281	164	187	258	507	365	306	313	363	352	320	318	315	363	352

Common Stock	0.06	0.06	0.07	0.08	0.09	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10
Preferred Stock	14.58	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Retained Earnings	-556	-698	-771	-817	-828	-840	-696	-757	-841	-907	-909	-865	-867	-904	-907	-909
Additional Paid-In Capital	605	624	770	881	828	906	986	1,000	1,014	1,077	1,092	1,016	1,020	1,074	1,077	1,092
Total Equity	67.18	-72.13	2.66	68.56	0.87	67.09	292	245	171	183	201	151	154	170	183	201
Cashflow Statement	Annuals (USD $) View: $ %											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	TTM	Mar12	Jun12	Sep12	Dec12	Mar13

Net Income	-95.00	-143	-72.40	-45.90	-10.99	-11.96	151	-61.25	-84.80	-65.48	-65.48	--	--	--	-65.48	--
Depreciation, Depletion and Amortization	12.25	12.17	9.69	7.22	6.77	6.82	11.33	9.18	11.78	10.76	10.76	--	--	--	10.76	--
Cash Flow from Others	-12.73	28.58	0.97	-14.54	40.32	217	-270	-11.52	-41.78	56.60	52.73	-6.71	-2.58	-24.87	90.76	-10.58
Cash Flow from Operations	-95.47	-102	-61.74	-53.23	36.09	212	-108	-63.59	-115	1.88	-1.99	-6.71	-2.58	-24.87	36.04	-10.58

Investment for Property, Plant & Equipement	-7.55	-3.53	-0.42	-2.56	-5.01	-17.07	-16.29	-17.56	-11.00	-5.17	-5.63	-0.46	-1.99	-1.36	-1.36	-0.92
Cash Flow from Acquisitions	--	--	--	--	-80.40	--	--	--	--	--	--	--	--	--	--	--
Cash Flow from Investing	-15.12	83.73	0.54	-32.61	-55.64	-234	-212	23.69	111	18.00	3.22	-0.52	24.09	-10.61	5.04	-15.31

Net Issuance of Stock	1.70	4.05	49.17	86.36	11.35	103	13.16	4.36	3.57	9.47	20.66	0.64	0.98	6.17	1.68	11.82
Net Issuance of Debt	40.15	8.10	-11.57	-7.85	22.30	-2.24	3.57	0.34	-4.24	29.66	29.38	-2.49	6.76	28.23	-2.83	-2.77
Other Financing	0.00	--	--	70.95	10.00	7.05	185	--	-0.00	0.00	-0.00	0.00	0.00	-0.00	-0.00	--
Cash Flow from Financing	41.85	12.15	37.60	149	43.65	108	202	4.70	-0.67	39.13	50.03	-1.85	7.74	34.40	-1.15	9.05

Net Change in Cash	-68.74	-5.87	-23.60	63.63	24.10	85.37	-119	-35.20	-4.58	59.01	51.26	-9.09	29.25	-1.08	39.92	-16.83

Free Cash Flow	-103	-105	-62.16	-55.78	31.08	195	-125	-81.15	-126	-3.29	-7.62	-7.17	-4.57	-26.23	34.68	-11.50
Valuation Ratios (Daily)	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

PE Ratio(ttm)
Price to Tangible Book
Price-to-Free-Cash-Flow ratio
PS Ratio
EV-to-Revenue
Forward Rate of Return
Shiller PE Ratio
Valuation and Quality	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

Market Cap
Enterprise Value
Month End Stock Price
Net Cash (per share)
Net Current Asset Value (per share)
DCF (per share)
Median PS (per share)
Peter Lynch Fair Value (per share)
Graham Number (per share)
Altman Z-Score
Piotroski F-Score
Beneish M-Score

Switch to Another Stock:

ISIS Quarterly/Annuals Reports

ISIS: 10-Q - ISIS PHARMACEUTICALS INC (0000874015) (Filer): (10-Q) - 2012-11-06
ISIS: 10-Q - ISIS PHARMACEUTICALS INC (0000874015) (Filer): (10-Q) - 2012-08-06
ISIS: 10-Q - ISIS PHARMACEUTICALS INC (0000874015) (Filer): (10-Q) - 2012-05-08
ISIS: 10-Q - ISIS PHARMACEUTICALS INC (0000874015) (Filer): (10-Q) - 2011-11-07
ISIS: 10-Q - ISIS PHARMACEUTICALS INC (0000874015) (Filer): (10-Q) - 2011-08-05

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names

Home About Jobs Advertise Site Map Term of Use Privacy Policy RSS Email Alerts Affiliate Program FAQ Contact Us
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.

FocusBar

Home

Premium Membership

Value Screens

Model Portfolios

Guru Stocks

Market Valuation

By Country

Articles

Submit Articles

ISIS Quarterly/Annuals Reports